双价马立克疫苗协同防淋巴瘤的机制研究
研究以新孵化雏鸡为对象,比较SB-1与HVT单价及双价疫苗接种后5天攻毒MDV的效果。双价苗在PBMC中抑制MDV复制与抑瘤能力优于单价苗,SB-1在脾脏持续复制而HVT仅1天在法氏囊复制,法氏囊为HVT保护所必需。
要点
- 双价SB-1+HVT苗抑制PBMC中MDV复制及肿瘤形成优于单价苗
- SB-1在脾脏复制持续至攻毒后14天,HVT仅攻毒后1天在法氏囊复制
- 法氏囊是HVT复制及诱导免疫保护的必要器官
核心结论
- SB-1与HVT双价疫苗的协同作用源于两苗在不同时间与靶器官的加性效应。
- 法氏囊对HVT复制及诱导免疫保护至关重要。
研究设计与样本
- 三项实验:新孵化雏鸡分别接种SB-1或HVT单价苗或双价苗,5天后以MDV攻毒。
- 实验1测PBMC中MDV复制水平及肿瘤发生率与保护力;实验2于攻毒后1、5、10、14天测淋巴器官中MDV与疫苗株复制;实验3对部分雏鸡切除法氏囊后接种攻毒评估保护力。
主要发现
- 双价SB-1+HVT苗在直至研究结束控制PBMC中致病性MDV水平优于SB-1或HVT单价苗,并与抑制肿瘤形成相关。
- SB-1在脾脏的复制从攻毒后1天增至14天,而HVT仅在攻毒后1天于法氏囊复制。
- 切除法氏囊后HVT疫苗诱导的免疫保护必需法氏囊。
临床怎么用
- 双价SB-1+HVT苗通过不同时间与靶器官的加性效应增强对MDV复制与肿瘤形成的控制。
- HVT疫苗免疫保护依赖法氏囊,法氏囊完整性对HVT诱导保护至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Marek's disease (MD) is a lymphoproliferative disease of chickens caused by Marek's disease virus (MDV), an oncogenic α-herpesvirus. Since 1970, MD has been controlled by widespread vaccination; however, more effective MD vaccines are needed to counter more virulent MDV strains. The bivalent vaccine combination of SB-1 and herpesvirus of turkey (HVT) strain FC126 has been widely used. Nonetheless, the mechanism(s) underlying this synergistic effect has not been investigated. METHODS: Three experiments were conducted where SB-1 or HVT were administered as monovalent or bivalent vaccines to newly hatched chickens, then challenged five days later with MDV. In Experiment 1, levels of MDV replication in PBMCs were measured over time, and tumor incidence and vaccinal protection determined. In Experiment 2, MDV and vaccine strains replication levels in lymphoid organs were measured at 1, 5, 10, and 14 days post-challenge (DPC). In Experiment 3, to verify that the bursa was necessary for HVT protection, a subset of chicks were bursectomized and these birds plus controls were similarly vaccinated and challenged, and the levels of vaccinal protection determined. RESULTS: The efficacy of bivalent SB-1 + HVT surpasses that of either SB-1 or HVT monovalent vaccines in controlling the level of pathogenic MDV in PBMCs until the end of the study, and this correlated with the ability to inhibit tumor formation. SB-1 replication in the spleen increased from 1 to 14 DPC, while HVT replicated only in the bursa at 1 DPC. The bursa was necessary for immune protection induced by HVT vaccine. CONCLUSION: Synergy of SB-1 and HVT vaccines is due to additive influences of the individual vaccines acting at different times and target organs. And the bursa is vital for HVT to replicate and induce immune protection.
引用
- Umthong S, Dunn JR, Cheng HH, et al. Towards a mechanistic understanding of the synergistic response induced by bivalent Marek's disease vaccines to prevent lymphomas. Vaccine. 2019. PMID: 31515142. doi:10.1016/j.vaccine.2019.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。